{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
omaveloxolone
to a specific field?
There is one exact (name or code) match for omaveloxolone
Status:
US Approved Rx
(2023)
Source:
NDA216718
(2023)
Source URL:
First approved in 2023
Source:
NDA216718
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Omaveloxolone (RTA-408) is a synthetic triterpenoid exerting antioxidant inflammation modulator properties. It activates the transcription factor Nrf2 and inhibits NF-κB signaling. Omaveloxolone demonstrated antioxidant, anti-inflammatory, and anticancer activities. Reata Pharmaceuticals is developing omaveloxolone for the treatment of cancers, Friedreich's ataxia and mitochondrial disorders.
Showing 1 - 3 of 3 results
Status:
US Approved Rx
(2023)
Source:
NDA216718
(2023)
Source URL:
First approved in 2023
Source:
NDA216718
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Omaveloxolone (RTA-408) is a synthetic triterpenoid exerting antioxidant inflammation modulator properties. It activates the transcription factor Nrf2 and inhibits NF-κB signaling. Omaveloxolone demonstrated antioxidant, anti-inflammatory, and anticancer activities. Reata Pharmaceuticals is developing omaveloxolone for the treatment of cancers, Friedreich's ataxia and mitochondrial disorders.
Status:
Other
Class:
MIXTURE
